Company Description
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of therapeutic products and services for endocrine and orphan lung diseases in the United States.
It offers Afrezza Inhalation Powder, an inhaled insulin used to improve glycemic control in adults with diabetes; the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults; and Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension.
The company’s product pipeline includes MNKD-101, a nebulized formulation of clofazimine, which is in Phase 3 study, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, which is in phase 1 clinical study, for the treatment of idiopathic pulmonary fibrosis (IPF); MNKD-301, which is in preclinical stage, for cystic fibrosis; and Pediatric Afrezza, which is in phase 3 clinical trial for the treatment of diabetes mellitus.
It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis.
Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India; and co-promotion agreement with Amphastar for marketing of Baqsimi (glucagon) nasal powder.
MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
| Country | United States |
| Founded | 1991 |
| IPO Date | Jul 28, 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 407 |
| CEO | Michael Castagna |
Contact Details
Address: 1 Casper Street Danbury, Connecticut 06810 United States | |
| Phone | 818 661 5000 |
| Website | mannkindcorp.com |
Stock Details
| Ticker Symbol | MNKD |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000899460 |
| CUSIP Number | 56400P706 |
| ISIN Number | US56400P7069 |
| Employer ID | 13-3607736 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Michael E. Castagna Pharm.D. | Chief Executive Officer and Director |
| Christopher B. Prentiss M.B.A. | Chief Financial Officer |
| Lauren M. Sabella | Executive Vice President of Operations |
| Dr. David B. Thomson J.D., Ph.D. | Executive Vice President, General Counsel and Secretary |
| Dr. Burkhard Blank M.D. | Executive Vice President of Research and Development and Chief Medical Officer |
| Sanjay Singh M.B.A. | Executive Vice President of Technical Operations |
| Rosabel Realica Alinaya CPA | Vice President of Investor Relations and Treasury |
| Dr. Stuart A. Tross Ph.D. | Executive Vice President of Human Resources |
| John F. Bedard | Senior Vice President of Worldwide Regulatory Affairs |
| Dr. Kevin Kaiserman M.D. | Senior Vice President and Therapeutic Area Head of Endocrine Diseases |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 1, 2025 | ARS | Filing |
| Apr 1, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 1, 2025 | DEF 14A | Other definitive proxy statements |
| Feb 26, 2025 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Feb 26, 2025 | 10-K | Annual Report |
| Feb 26, 2025 | 8-K | Current Report |
| Jan 6, 2025 | 8-K | Current Report |
| Dec 18, 2024 | 8-K | Current Report |
| Nov 22, 2024 | 144 | Filing |
| Nov 15, 2024 | 144 | Filing |